- $338.28m
- $133.14m
Zura Bio Q2 net loss widens as R&D expenses rise
Zura Bio Ltd expected to post a loss of 20 cents a share - Earnings Preview
Brief: Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zura Bio Expands Leadership Team With Appointment Of Muzammil Mustufa As Chief Business Officer
Zura Bio Q1 net loss widens as expenses rise
Eric Hyllengren Separated From Zura Bio Limited As CFO On April 20, 2026
Zura Bio's FY net loss widens on higher R&D costs
Brief: Zura Bio Announces Closing Of Its $144 Million Public Offering
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Zura Bio falls on $125 mln stock sale
Brief: Zura Bio Announces Pricing Of $125 Million Public Offering Of Class A Ordinary Shares And Pre-Funded Warrants
Zura Bio falls after commencing stock offering
Brief: Zura Bio Welcomes Accomplished Drug Development Leaders To Board Of Directors
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
Zura Bio names new CEO; shares rise
Brief: Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. As CEO
On Dec 29, Co And Units Entered Into Several Agreements